Meas Healthy (02415.HK) subsidiary wins bid for a large real-world research project "Gout Wisdom Management Plan" for a pharmaceutical company in China.

Zhixin Financial News App News, Meinian Health (02415.HK) announced that recently, the company's subsidiary Shanghai Meinian Pharmaceutical Technology Co., Ltd. successfully bid for a large real-world research project from a Chinese pharmaceutical company. The project aims to "evaluate the effectiveness and safety of IL-1 monoclonal antibody treatment for patients with acute and intermittent gout through a combination of prospective and retrospective observational studies." The project is worth approximately 21 million yuan.